此页面是自动翻译的，不保证翻译的准确性。请参阅英文版对于源文本。

搜索临床试验以：Androgen Pathway Modulation-Sensitive

总计3824个结果

Washington University School of Medicine
ImmunityBio, Inc.; Dendreon

尚未招聘

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

前列腺癌 | 转移性前列腺癌

美国
Novartis Pharmaceuticals

招聘中

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

前列腺肿瘤，去势抵抗

美国
Prostate Cancer Clinical Trials Consortium
Pfizer; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center

尚未招聘

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy (MOMENT)

前列腺癌（腺癌） | 转移性去势抵抗性前列腺癌 (mCRPC)
Novartis Pharmaceuticals

招聘中

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

转移性去势抵抗性前列腺癌 (mCRPC)

澳大利亚, 美国, 加拿大, 韩国, 日本
Bayer

招聘中

一项关于美国泌尿科诊所中达罗他胺及其他雄激素受体通路抑制剂（ARPIs）用于新诊断转移性激素敏感性前列腺癌（de Novo mHSPC）真实世界使用情况和结果的研究 (Double-DARE)

前列腺肿瘤 | 转移性激素敏感性前列腺癌

美国

这是预览

登录或创建免费账户，即可查看所有匹配的试验并使用完整搜索功能。

登录注册